Integral Diagnostics 향후 성장

Future 기준 점검 4/6

Integral Diagnostics (는) 각각 연간 31.3% 및 9.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 31.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.3% 로 예상됩니다.

핵심 정보

31.3%

이익 성장률

31.15%

EPS 성장률

Healthcare 이익 성장	18.8%
매출 성장률	9.7%
향후 자기자본이익률	9.30%
애널리스트 커버리지	Good
마지막 업데이트	21 Nov 2025

최근 향후 성장 업데이트

Recent updates

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Apr 27 Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Feb 28

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

이익 및 매출 성장 예측

ASX:IDX - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
6/30/2028	907	69	77	148	8
6/30/2027	854	58	68	135	10
6/30/2026	805	48	68	120	10
6/30/2025	627	5	14	74	N/A
3/31/2025	559	5	24	73	N/A
12/31/2024	491	6	34	73	N/A
9/30/2024	481	-28	38	70	N/A
6/30/2024	470	-61	42	66	N/A
3/31/2024	463	-59	29	62	N/A
12/31/2023	456	-58	16	58	N/A
9/30/2023	449	-16	20	63	N/A
6/30/2023	441	25	23	67	N/A
3/31/2023	418	23	20	56	N/A
12/31/2022	395	21	17	45	N/A
9/30/2022	378	18	13	41	N/A
6/30/2022	361	15	9	37	N/A
3/31/2022	361	18	14	41	N/A
12/31/2021	360	22	18	44	N/A
9/30/2021	356	26	34	57	N/A
6/30/2021	351	31	49	70	N/A
3/31/2021	333	32	54	73	N/A
12/31/2020	315	32	59	76	N/A
9/30/2020	295	28	44	65	N/A
6/30/2020	276	23	28	54	N/A
3/31/2020	263	22	19	47	N/A
12/31/2019	250	21	9	39	N/A
9/30/2019	241	21	12	37	N/A
6/30/2019	232	21	15	34	N/A
3/31/2019	222	19	N/A	30	N/A
12/31/2018	211	17	N/A	26	N/A
9/30/2018	200	16	N/A	26	N/A
6/30/2018	189	15	N/A	27	N/A
3/31/2018	187	15	N/A	27	N/A
12/31/2017	185	15	N/A	27	N/A
9/30/2017	182	15	N/A	25	N/A
6/30/2017	180	15	N/A	23	N/A
3/31/2017	177	16	N/A	26	N/A
12/31/2016	175	16	N/A	30	N/A
9/30/2016	171	14	N/A	27	N/A
6/30/2016	168	11	N/A	24	N/A
3/31/2016	165	11	N/A	22	N/A
12/31/2015	162	11	N/A	20	N/A
9/30/2015	157	8	N/A	18	N/A
6/30/2015	151	5	N/A	17	N/A

애널리스트 향후 성장 전망

수입 대 저축률: IDX 의 연간 예상 수익 증가율(31.3%)이 saving rate(3.3%)보다 높습니다.

수익 vs 시장: IDX 의 연간 수익(31.3%)이 Australian 시장(12%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: IDX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: IDX 의 수익(연간 9.7%)이 Australian 시장(연간 5.9%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: IDX 의 수익(연간 9.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: IDX의 자본 수익률은 3년 후 9.3%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/25 15:12
종가	2025/11/25 00:00
수익	2025/06/30
연간 수익	2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Integral Diagnostics Limited는 19명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Benjamin Brayshaw	Barrenjoey Markets Pty Limited
Thomas Yeo	Barrenjoey Markets Pty Limited
Saul Hadassin	Barrenjoey Markets Pty Limited

Integral Diagnostics 향후 성장

Future 기준 점검 4/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 7.1% to AU$3.34

Consensus EPS estimates fall by 14%

Price target decreased by 7.3% to AU$3.15

Price target increased by 7.7% to AU$2.93

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Recent updates

New major risk - Dividend sustainability

Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025

Final dividend increased to AU$0.04

Price target increased by 7.1% to AU$3.34

Full year 2025 earnings released: EPS: AU$0.016 (vs AU$0.26 loss in FY 2024)

Consensus EPS estimates fall by 14%

New minor risk - Dividend sustainability

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Private Equity Players Reportedly Keep Close Tabs on Integral Diagnostics

Independent Non-Executive Chairman recently bought AU$79k worth of stock

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

First half dividend of announced

Price target decreased by 7.3% to AU$3.15

First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive Director

Integral Diagnostics Limited Announces Company Secretary Changes

New major risk - Shareholder dilution

High number of new directors

Integral Diagnostics Limited Announces Board Appointments

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).

Integral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Price target increased by 7.7% to AU$2.93

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate